NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Hubei Biocause Pharmaceutical Co. Ltd (SHE: 000627)
000627 Technical Analysis
2
As on 30th Apr 2025 000627 STOCK Price closed @ 2.74 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.46 & Strong Sell for SHORT-TERM with Stoploss of 2.97 we also expect STOCK to react on Following IMPORTANT LEVELS. |
000627STOCK Price
Open | 2.74 | Change | Price | % |
High | 2.89 | 1 Day | -0.30 | -9.87 |
Low | 2.74 | 1 Week | -0.80 | -22.60 |
Close | 2.74 | 1 Month | -1.29 | -32.01 |
Volume | 276847735 | 1 Year | -0.34 | -11.04 |
52 Week High 5.18 | 52 Week Low 1.64 |
SHE China Most Active Stocks
002131 | 3.94 | 0.25% |
002195 | 5.84 | -0.85% |
000981 | 2.07 | 10.11% |
002354 | 7.07 | -3.68% |
002165 | 12.38 | -9.50% |
000725 | 3.88 | 0.26% |
000627 | 2.74 | -9.87% |
300059 | 21.22 | -0.14% |
300008 | 6.57 | 0.46% |
002607 | 3.16 | 2.93% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
000627 Daily Charts |
000627 Intraday Charts |
Whats New @ Bazaartrend |
000627 Free Analysis |
|
000627 Important Levels Intraday
RESISTANCE | 3.03 |
RESISTANCE | 2.94 |
RESISTANCE | 2.88 |
RESISTANCE | 2.82 |
SUPPORT | 2.66 |
SUPPORT | 2.60 |
SUPPORT | 2.54 |
SUPPORT | 2.45 |
000627 Forecast May 2025
4th UP Forecast | 3.51 |
3rd UP Forecast | 3.26 |
2nd UP Forecast | 3.11 |
1st UP Forecast | 2.96 |
1st DOWN Forecast | 2.52 |
2nd DOWN Forecast | 2.37 |
3rd DOWN Forecast | 2.22 |
4th DOWN Forecast | 1.97 |
000627 Weekly Forecast
4th UP Forecast | 3.11 |
3rd UP Forecast | 2.99 |
2nd UP Forecast | 2.92 |
1st UP Forecast | 2.84 |
1st DOWN Forecast | 2.64 |
2nd DOWN Forecast | 2.56 |
3rd DOWN Forecast | 2.49 |
4th DOWN Forecast | 2.37 |
000627 Forecast2025
4th UP Forecast | 10.08 |
3rd UP Forecast | 7.73 |
2nd UP Forecast | 6.27 |
1st UP Forecast | 4.82 |
1st DOWN Forecast | 0.66 |
2nd DOWN Forecast | -0.79 |
3rd DOWN Forecast | -2.25 |
4th DOWN Forecast | -4.6 |
Hubei Biocause Pharmaceutical Co. Ltd ( SHE China Symbol : 000627 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
000627 Other Details
Segment | EQ | |
Market Capital | 15958235136.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
000627 Address
![]() |
000627 Latest News
000627 Business Profile
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China. Address: 122-132 Yangwan Road, Jingmen, China, 448000
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service